Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-06-02

AUTHORS

Linea N. Toksvang, Shawn H. R. Lee, Jun J. Yang, Kjeld Schmiegelow

ABSTRACT

Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with nucleotide synthesis and salvage pathways. The primary cytotoxic mechanism involves the incorporation of thioguanine nucleotides (TGNs) into DNA (as DNA-TG), which may be enhanced by the inhibition of de novo purine synthesis by other MTX/6-MP metabolites. Co-medication during MT is common. Although Pneumocystis jirovecii prophylaxis appears safe, the benefit of glucocorticosteroid/vincristine pulses in improving survival and of allopurinol to moderate 6-MP pharmacokinetics remains uncertain. Numerous genetic polymorphisms influence the pharmacology, efficacy, and toxicity (mainly myelosuppression and hepatotoxicity) of MTX and thiopurines. Thiopurine S-methyltransferase (encoded by TPMT) decreases TGNs but increases methylated 6-MP metabolites (MeMPs); similarly, nudix hydrolase 15 (encoded by NUDT15) also decreases TGNs available for DNA incorporation. Loss-of-function variants in both genes are currently used to guide MT, but do not fully explain the inter-patient variability in thiopurine toxicity. Because of the large inter-individual variations in MTX/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy—the addition of low-dose (2.5–12.5 mg/m2/day) 6-thioguanine to the 6-MP/MTX backbone—that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk. More... »

PAGES

1749-1758

References to SciGraph publications

  • 2004-04. Methylated Metabolites of 6‐mercaptopurine are Associated with Hepatotoxicity in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2015-03-19. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia in NATURE COMMUNICATIONS
  • 2016-09-06. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-10-15. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-01-17. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia in NATURE
  • 2015-06-08. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951 in LEUKEMIA
  • 2021-09-17. DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia in LEUKEMIA
  • 2018-02-01. Role of TPMT and ITPA variants in mercaptopurine disposition in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-05-11. Negative feedback–defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL in NATURE MEDICINE
  • 2011-10-19. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2021-03-13. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia in LEUKEMIA
  • 2020-04-13. The impact of maintenance therapy on sleep-wake rhythms and cancer-related fatigue in pediatric acute lymphoblastic leukemia in SUPPORTIVE CARE IN CANCER
  • 2021-06-26. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis in LEUKEMIA
  • 1998-08. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1996-03. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2008-01. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer in NATURE REVIEWS CANCER
  • 2017-10-06. Clonal evolution in leukemia in NATURE MEDICINE
  • 2013-02-03. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia in NATURE GENETICS
  • 2021-04-29. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2002-02-01. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine in LEUKEMIA
  • 2018-09-10. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia in LEUKEMIA
  • 2008-11-06. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study in LEUKEMIA
  • 2011-03-04. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia in LEUKEMIA
  • 2016-10-04. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children in LEUKEMIA
  • 2016-02-15. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity in NATURE GENETICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/s41375-022-01591-4

    DOI

    http://dx.doi.org/10.1038/s41375-022-01591-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1148378314

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35654820


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mercaptopurine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Methotrexate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Methyltransferases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recurrence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Thioguanine", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark", 
              "id": "http://www.grid.ac/institutes/grid.475435.4", 
              "name": [
                "Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Toksvang", 
            "givenName": "Linea N.", 
            "id": "sg:person.01305767704.90", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305767704.90"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore", 
              "id": "http://www.grid.ac/institutes/grid.4280.e", 
              "name": [
                "Department of Pharmacy and Pharmaceutical Sciences, St Jude Children\u2019s Research Hospital, Memphis, TN, USA", 
                "Khoo Teck Puat\u2013National University Children\u2019s Medical Institute, National University Hospital, National University Health System, Singapore, Singapore", 
                "Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lee", 
            "givenName": "Shawn H. R.", 
            "id": "sg:person.010050277747.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010050277747.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, St Jude Children\u2019s Research Hospital, Memphis, TN, USA", 
              "id": "http://www.grid.ac/institutes/grid.240871.8", 
              "name": [
                "Department of Pharmacy and Pharmaceutical Sciences, St Jude Children\u2019s Research Hospital, Memphis, TN, USA", 
                "Department of Oncology, St Jude Children\u2019s Research Hospital, Memphis, TN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yang", 
            "givenName": "Jun J.", 
            "id": "sg:person.016373210004.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016373210004.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark", 
              "id": "http://www.grid.ac/institutes/grid.5254.6", 
              "name": [
                "Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark", 
                "Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schmiegelow", 
            "givenName": "Kjeld", 
            "id": "sg:person.0716465116.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716465116.51"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00280-021-04281-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1137615989", 
              "https://doi.org/10.1007/s00280-021-04281-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature25186", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100458150", 
              "https://doi.org/10.1038/nature25186"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.4410", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092115488", 
              "https://doi.org/10.1038/nm.4410"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.3508", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013931386", 
              "https://doi.org/10.1038/ng.3508"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800050405", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036687181", 
              "https://doi.org/10.1007/s002800050405"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-018-0245-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1106904507", 
              "https://doi.org/10.1038/s41375-018-0245-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2402373", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031069123", 
              "https://doi.org/10.1038/sj.leu.2402373"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-018-3704-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1107643891", 
              "https://doi.org/10.1007/s00280-018-3704-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.2558", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000045671", 
              "https://doi.org/10.1038/ng.2558"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2011.37", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044318668", 
              "https://doi.org/10.1038/leu.2011.37"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1016/j.clpt.2003.12.001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039519767", 
              "https://doi.org/10.1016/j.clpt.2003.12.001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc2292", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014136589", 
              "https://doi.org/10.1038/nrc2292"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-021-01182-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1139172444", 
              "https://doi.org/10.1038/s41375-021-01182-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2015.134", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033384211", 
              "https://doi.org/10.1038/leu.2015.134"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-021-01203-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1136365011", 
              "https://doi.org/10.1038/s41375-021-01203-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-016-3151-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013312415", 
              "https://doi.org/10.1007/s00280-016-3151-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00520-020-05444-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1126642640", 
              "https://doi.org/10.1007/s00520-020-05444-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms7604", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042226470", 
              "https://doi.org/10.1038/ncomms7604"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800050816", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037384717", 
              "https://doi.org/10.1007/s002800050816"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-018-3525-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100738149", 
              "https://doi.org/10.1007/s00280-018-3525-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2008.316", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001000021", 
              "https://doi.org/10.1038/leu.2008.316"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00228-011-1133-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021555358", 
              "https://doi.org/10.1007/s00228-011-1133-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-021-01420-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1141186678", 
              "https://doi.org/10.1038/s41375-021-01420-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2016.274", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003672238", 
              "https://doi.org/10.1038/leu.2016.274"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.3840", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033127948", 
              "https://doi.org/10.1038/nm.3840"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-06-02", 
        "datePublishedReg": "2022-06-02", 
        "description": "Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with nucleotide synthesis and salvage pathways. The primary cytotoxic mechanism involves the incorporation of thioguanine nucleotides (TGNs) into DNA (as DNA-TG), which may be enhanced by the inhibition of de novo purine synthesis by other MTX/6-MP metabolites. Co-medication during MT is common. Although Pneumocystis jirovecii prophylaxis appears safe, the benefit of glucocorticosteroid/vincristine pulses in improving survival and of allopurinol to moderate 6-MP pharmacokinetics remains uncertain. Numerous genetic polymorphisms influence the pharmacology, efficacy, and toxicity (mainly myelosuppression and hepatotoxicity) of MTX and thiopurines. Thiopurine S-methyltransferase (encoded by TPMT) decreases TGNs but increases methylated 6-MP metabolites (MeMPs); similarly, nudix hydrolase 15 (encoded by NUDT15) also decreases TGNs available for DNA incorporation. Loss-of-function variants in both genes are currently used to guide MT, but do not fully explain the inter-patient variability in thiopurine toxicity. Because of the large inter-individual variations in MTX/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy\u2014the addition of low-dose (2.5\u201312.5\u2009mg/m2/day) 6-thioguanine to the 6-MP/MTX backbone\u2014that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/s41375-022-01591-4", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.9644834", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1097065", 
            "issn": [
              "0887-6924", 
              "1476-5551"
            ], 
            "name": "Leukemia", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "36"
          }
        ], 
        "keywords": [
          "acute lymphoblastic leukemia", 
          "maintenance therapy", 
          "thioguanine nucleotides", 
          "DNA-TG", 
          "lymphoblastic leukemia", 
          "Pneumocystis jirovecii prophylaxis", 
          "nudix hydrolase 15", 
          "degree of myelosuppression", 
          "large inter-individual variation", 
          "inter-patient variability", 
          "mismatch repair genes", 
          "thiopurine S-methyltransferase", 
          "relapse hazard", 
          "oral methotrexate", 
          "salvage therapy", 
          "dose adjustment", 
          "combination chemotherapy", 
          "numerous genetic polymorphisms", 
          "relapse risk", 
          "imminent relapse", 
          "primary cytotoxic mechanism", 
          "methotrexate", 
          "therapy", 
          "thiopurine toxicity", 
          "function variants", 
          "thiopurines", 
          "inter-individual variation", 
          "treatment intensity", 
          "genetic polymorphisms", 
          "cytotoxic mechanism", 
          "S-methyltransferase", 
          "relapse", 
          "de novo purine synthesis", 
          "repair genes", 
          "development of strategies", 
          "leukemia", 
          "DNA incorporation", 
          "clinical translation", 
          "downstream metabolites", 
          "novo purine synthesis", 
          "metabolism pathways", 
          "basic science", 
          "metabolites", 
          "nucleotide synthesis", 
          "toxicity", 
          "purine synthesis", 
          "salvage pathway", 
          "prophylaxis", 
          "myelosuppression", 
          "high levels", 
          "chemotherapy", 
          "allopurinol", 
          "pharmacokinetics", 
          "pathway", 
          "trials", 
          "pharmacology", 
          "efficacy", 
          "cure", 
          "survival", 
          "risk", 
          "inhibition", 
          "genes", 
          "metabolism", 
          "bioavailability", 
          "polymorphism", 
          "mutations", 
          "frontline", 
          "interferes", 
          "adjustment", 
          "levels", 
          "development", 
          "strategies", 
          "variants", 
          "benefits", 
          "increase", 
          "loss", 
          "changes", 
          "mechanism", 
          "DNA", 
          "incorporation", 
          "hazards", 
          "addition", 
          "nucleotides", 
          "valuable insights", 
          "degree", 
          "variability", 
          "translation", 
          "synthesis", 
          "intensity", 
          "insights", 
          "variation", 
          "science", 
          "pulses", 
          "maintenance strategy", 
          "backbone"
        ], 
        "name": "Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations", 
        "pagination": "1749-1758", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1148378314"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/s41375-022-01591-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35654820"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/s41375-022-01591-4", 
          "https://app.dimensions.ai/details/publication/pub.1148378314"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:07", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_929.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/s41375-022-01591-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01591-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01591-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01591-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41375-022-01591-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    320 TRIPLES      21 PREDICATES      152 URIs      119 LITERALS      14 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/s41375-022-01591-4 schema:about N183bb6926897428bbfec0f0cb1a0dade
    2 N4d6a672cd94e4ca4b4c9fbcf73d8008a
    3 N620126dfd8d943308830d9ea612ef8e3
    4 N9212658c6baf485db44c0b2f18d1fbed
    5 N9505dfafd81e4e4dbb23ea744ba978b5
    6 Nbef82662c8934a9eb75c24d395558f71
    7 Nc51cdc98fbed4a1797dcff20f290cc04
    8 anzsrc-for:11
    9 anzsrc-for:1102
    10 schema:author N5d7bffbb43194c5da4899178673ea4eb
    11 schema:citation sg:pub.10.1007/s00228-011-1133-1
    12 sg:pub.10.1007/s00280-016-3151-2
    13 sg:pub.10.1007/s00280-018-3525-8
    14 sg:pub.10.1007/s00280-018-3704-7
    15 sg:pub.10.1007/s00280-021-04281-7
    16 sg:pub.10.1007/s002800050405
    17 sg:pub.10.1007/s002800050816
    18 sg:pub.10.1007/s00520-020-05444-7
    19 sg:pub.10.1016/j.clpt.2003.12.001
    20 sg:pub.10.1038/leu.2008.316
    21 sg:pub.10.1038/leu.2011.37
    22 sg:pub.10.1038/leu.2015.134
    23 sg:pub.10.1038/leu.2016.274
    24 sg:pub.10.1038/nature25186
    25 sg:pub.10.1038/ncomms7604
    26 sg:pub.10.1038/ng.2558
    27 sg:pub.10.1038/ng.3508
    28 sg:pub.10.1038/nm.3840
    29 sg:pub.10.1038/nm.4410
    30 sg:pub.10.1038/nrc2292
    31 sg:pub.10.1038/s41375-018-0245-3
    32 sg:pub.10.1038/s41375-021-01182-9
    33 sg:pub.10.1038/s41375-021-01203-7
    34 sg:pub.10.1038/s41375-021-01420-0
    35 sg:pub.10.1038/sj.leu.2402373
    36 schema:datePublished 2022-06-02
    37 schema:datePublishedReg 2022-06-02
    38 schema:description Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with nucleotide synthesis and salvage pathways. The primary cytotoxic mechanism involves the incorporation of thioguanine nucleotides (TGNs) into DNA (as DNA-TG), which may be enhanced by the inhibition of de novo purine synthesis by other MTX/6-MP metabolites. Co-medication during MT is common. Although Pneumocystis jirovecii prophylaxis appears safe, the benefit of glucocorticosteroid/vincristine pulses in improving survival and of allopurinol to moderate 6-MP pharmacokinetics remains uncertain. Numerous genetic polymorphisms influence the pharmacology, efficacy, and toxicity (mainly myelosuppression and hepatotoxicity) of MTX and thiopurines. Thiopurine S-methyltransferase (encoded by TPMT) decreases TGNs but increases methylated 6-MP metabolites (MeMPs); similarly, nudix hydrolase 15 (encoded by NUDT15) also decreases TGNs available for DNA incorporation. Loss-of-function variants in both genes are currently used to guide MT, but do not fully explain the inter-patient variability in thiopurine toxicity. Because of the large inter-individual variations in MTX/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy—the addition of low-dose (2.5–12.5 mg/m2/day) 6-thioguanine to the 6-MP/MTX backbone—that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk.
    39 schema:genre article
    40 schema:isAccessibleForFree true
    41 schema:isPartOf N0609294060e34437ad1342a61d913110
    42 N065d051e329b41fd8f2c36700e6b80aa
    43 sg:journal.1097065
    44 schema:keywords DNA
    45 DNA incorporation
    46 DNA-TG
    47 Pneumocystis jirovecii prophylaxis
    48 S-methyltransferase
    49 acute lymphoblastic leukemia
    50 addition
    51 adjustment
    52 allopurinol
    53 backbone
    54 basic science
    55 benefits
    56 bioavailability
    57 changes
    58 chemotherapy
    59 clinical translation
    60 combination chemotherapy
    61 cure
    62 cytotoxic mechanism
    63 de novo purine synthesis
    64 degree
    65 degree of myelosuppression
    66 development
    67 development of strategies
    68 dose adjustment
    69 downstream metabolites
    70 efficacy
    71 frontline
    72 function variants
    73 genes
    74 genetic polymorphisms
    75 hazards
    76 high levels
    77 imminent relapse
    78 incorporation
    79 increase
    80 inhibition
    81 insights
    82 intensity
    83 inter-individual variation
    84 inter-patient variability
    85 interferes
    86 large inter-individual variation
    87 leukemia
    88 levels
    89 loss
    90 lymphoblastic leukemia
    91 maintenance strategy
    92 maintenance therapy
    93 mechanism
    94 metabolism
    95 metabolism pathways
    96 metabolites
    97 methotrexate
    98 mismatch repair genes
    99 mutations
    100 myelosuppression
    101 novo purine synthesis
    102 nucleotide synthesis
    103 nucleotides
    104 nudix hydrolase 15
    105 numerous genetic polymorphisms
    106 oral methotrexate
    107 pathway
    108 pharmacokinetics
    109 pharmacology
    110 polymorphism
    111 primary cytotoxic mechanism
    112 prophylaxis
    113 pulses
    114 purine synthesis
    115 relapse
    116 relapse hazard
    117 relapse risk
    118 repair genes
    119 risk
    120 salvage pathway
    121 salvage therapy
    122 science
    123 strategies
    124 survival
    125 synthesis
    126 therapy
    127 thioguanine nucleotides
    128 thiopurine S-methyltransferase
    129 thiopurine toxicity
    130 thiopurines
    131 toxicity
    132 translation
    133 treatment intensity
    134 trials
    135 valuable insights
    136 variability
    137 variants
    138 variation
    139 schema:name Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations
    140 schema:pagination 1749-1758
    141 schema:productId N0f135e2ca24c42cf851ac367cc3d0d7f
    142 N1a4075aed84c43d8a5ae321052449733
    143 N995bfae815de43ceada637d759afea7e
    144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1148378314
    145 https://doi.org/10.1038/s41375-022-01591-4
    146 schema:sdDatePublished 2022-09-02T16:07
    147 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    148 schema:sdPublisher N87e16c4398314104a624d58334ef9f8a
    149 schema:url https://doi.org/10.1038/s41375-022-01591-4
    150 sgo:license sg:explorer/license/
    151 sgo:sdDataset articles
    152 rdf:type schema:ScholarlyArticle
    153 N0609294060e34437ad1342a61d913110 schema:volumeNumber 36
    154 rdf:type schema:PublicationVolume
    155 N065d051e329b41fd8f2c36700e6b80aa schema:issueNumber 7
    156 rdf:type schema:PublicationIssue
    157 N0f135e2ca24c42cf851ac367cc3d0d7f schema:name doi
    158 schema:value 10.1038/s41375-022-01591-4
    159 rdf:type schema:PropertyValue
    160 N183bb6926897428bbfec0f0cb1a0dade schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Methyltransferases
    162 rdf:type schema:DefinedTerm
    163 N1a4075aed84c43d8a5ae321052449733 schema:name dimensions_id
    164 schema:value pub.1148378314
    165 rdf:type schema:PropertyValue
    166 N278c1d3520e14db38ddbf71d0318b833 rdf:first sg:person.010050277747.81
    167 rdf:rest Na5336fc509ab43b093dcf77606b3f720
    168 N4d6a672cd94e4ca4b4c9fbcf73d8008a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Thioguanine
    170 rdf:type schema:DefinedTerm
    171 N5d7bffbb43194c5da4899178673ea4eb rdf:first sg:person.01305767704.90
    172 rdf:rest N278c1d3520e14db38ddbf71d0318b833
    173 N620126dfd8d943308830d9ea612ef8e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Methotrexate
    175 rdf:type schema:DefinedTerm
    176 N87e16c4398314104a624d58334ef9f8a schema:name Springer Nature - SN SciGraph project
    177 rdf:type schema:Organization
    178 N9212658c6baf485db44c0b2f18d1fbed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Humans
    180 rdf:type schema:DefinedTerm
    181 N9505dfafd81e4e4dbb23ea744ba978b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Recurrence
    183 rdf:type schema:DefinedTerm
    184 N995bfae815de43ceada637d759afea7e schema:name pubmed_id
    185 schema:value 35654820
    186 rdf:type schema:PropertyValue
    187 Na5336fc509ab43b093dcf77606b3f720 rdf:first sg:person.016373210004.51
    188 rdf:rest Na6c150637a454efb8535c237a4c6d7f2
    189 Na6c150637a454efb8535c237a4c6d7f2 rdf:first sg:person.0716465116.51
    190 rdf:rest rdf:nil
    191 Nbef82662c8934a9eb75c24d395558f71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Mercaptopurine
    193 rdf:type schema:DefinedTerm
    194 Nc51cdc98fbed4a1797dcff20f290cc04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Precursor Cell Lymphoblastic Leukemia-Lymphoma
    196 rdf:type schema:DefinedTerm
    197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    198 schema:name Medical and Health Sciences
    199 rdf:type schema:DefinedTerm
    200 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    201 schema:name Cardiorespiratory Medicine and Haematology
    202 rdf:type schema:DefinedTerm
    203 sg:grant.9644834 http://pending.schema.org/fundedItem sg:pub.10.1038/s41375-022-01591-4
    204 rdf:type schema:MonetaryGrant
    205 sg:journal.1097065 schema:issn 0887-6924
    206 1476-5551
    207 schema:name Leukemia
    208 schema:publisher Springer Nature
    209 rdf:type schema:Periodical
    210 sg:person.010050277747.81 schema:affiliation grid-institutes:grid.4280.e
    211 schema:familyName Lee
    212 schema:givenName Shawn H. R.
    213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010050277747.81
    214 rdf:type schema:Person
    215 sg:person.01305767704.90 schema:affiliation grid-institutes:grid.475435.4
    216 schema:familyName Toksvang
    217 schema:givenName Linea N.
    218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305767704.90
    219 rdf:type schema:Person
    220 sg:person.016373210004.51 schema:affiliation grid-institutes:grid.240871.8
    221 schema:familyName Yang
    222 schema:givenName Jun J.
    223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016373210004.51
    224 rdf:type schema:Person
    225 sg:person.0716465116.51 schema:affiliation grid-institutes:grid.5254.6
    226 schema:familyName Schmiegelow
    227 schema:givenName Kjeld
    228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716465116.51
    229 rdf:type schema:Person
    230 sg:pub.10.1007/s00228-011-1133-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021555358
    231 https://doi.org/10.1007/s00228-011-1133-1
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1007/s00280-016-3151-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013312415
    234 https://doi.org/10.1007/s00280-016-3151-2
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1007/s00280-018-3525-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100738149
    237 https://doi.org/10.1007/s00280-018-3525-8
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1007/s00280-018-3704-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107643891
    240 https://doi.org/10.1007/s00280-018-3704-7
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1007/s00280-021-04281-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137615989
    243 https://doi.org/10.1007/s00280-021-04281-7
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1007/s002800050405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036687181
    246 https://doi.org/10.1007/s002800050405
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1007/s002800050816 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037384717
    249 https://doi.org/10.1007/s002800050816
    250 rdf:type schema:CreativeWork
    251 sg:pub.10.1007/s00520-020-05444-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1126642640
    252 https://doi.org/10.1007/s00520-020-05444-7
    253 rdf:type schema:CreativeWork
    254 sg:pub.10.1016/j.clpt.2003.12.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039519767
    255 https://doi.org/10.1016/j.clpt.2003.12.001
    256 rdf:type schema:CreativeWork
    257 sg:pub.10.1038/leu.2008.316 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001000021
    258 https://doi.org/10.1038/leu.2008.316
    259 rdf:type schema:CreativeWork
    260 sg:pub.10.1038/leu.2011.37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044318668
    261 https://doi.org/10.1038/leu.2011.37
    262 rdf:type schema:CreativeWork
    263 sg:pub.10.1038/leu.2015.134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033384211
    264 https://doi.org/10.1038/leu.2015.134
    265 rdf:type schema:CreativeWork
    266 sg:pub.10.1038/leu.2016.274 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003672238
    267 https://doi.org/10.1038/leu.2016.274
    268 rdf:type schema:CreativeWork
    269 sg:pub.10.1038/nature25186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100458150
    270 https://doi.org/10.1038/nature25186
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1038/ncomms7604 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042226470
    273 https://doi.org/10.1038/ncomms7604
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.1038/ng.2558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000045671
    276 https://doi.org/10.1038/ng.2558
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.1038/ng.3508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013931386
    279 https://doi.org/10.1038/ng.3508
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1038/nm.3840 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033127948
    282 https://doi.org/10.1038/nm.3840
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1038/nm.4410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092115488
    285 https://doi.org/10.1038/nm.4410
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1038/nrc2292 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014136589
    288 https://doi.org/10.1038/nrc2292
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1038/s41375-018-0245-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106904507
    291 https://doi.org/10.1038/s41375-018-0245-3
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1038/s41375-021-01182-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139172444
    294 https://doi.org/10.1038/s41375-021-01182-9
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1038/s41375-021-01203-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136365011
    297 https://doi.org/10.1038/s41375-021-01203-7
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1038/s41375-021-01420-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141186678
    300 https://doi.org/10.1038/s41375-021-01420-0
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.1038/sj.leu.2402373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031069123
    303 https://doi.org/10.1038/sj.leu.2402373
    304 rdf:type schema:CreativeWork
    305 grid-institutes:grid.240871.8 schema:alternateName Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA
    306 schema:name Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA
    307 Department of Pharmacy and Pharmaceutical Sciences, St Jude Children’s Research Hospital, Memphis, TN, USA
    308 rdf:type schema:Organization
    309 grid-institutes:grid.4280.e schema:alternateName Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
    310 schema:name Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
    311 Department of Pharmacy and Pharmaceutical Sciences, St Jude Children’s Research Hospital, Memphis, TN, USA
    312 Khoo Teck Puat–National University Children’s Medical Institute, National University Hospital, National University Health System, Singapore, Singapore
    313 rdf:type schema:Organization
    314 grid-institutes:grid.475435.4 schema:alternateName Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
    315 schema:name Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
    316 rdf:type schema:Organization
    317 grid-institutes:grid.5254.6 schema:alternateName Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark
    318 schema:name Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
    319 Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark
    320 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...